Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the Integrase Inhibitor Raltegravir.

Trial Profile

Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the Integrase Inhibitor Raltegravir.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms RACING
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jan 2017 Results (n=221) assessing QoL outcomes in patients treated with raltegravir, published in the HIV Clinical Trials
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top